Synthesis of trans- and cis-4′-hydroxylomustine and development ofvalidated analytical method for lomustine and trans- and cis-4′- hydroxylomustine in canine plasma

Journal of Analytical Toxicology

Volumn 33, Issue 9, 2009, Pages 595-603

  Dirikolu, L ^a   Chakkath, T ^a   Fan, T ^a   Mente, Nolan R ^b  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b Obiter Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' HYDROXYLOMUSTINE [1 (2 CHLOROETHYL) 3 (4 HYDROXYCYCLOHEXYL) 1 NITROSOUREA)]; LOMUSTINE; NITROSOUREA DERIVATIVE; UNCLASSIFIED DRUG; [(1 (2 CHLOROETHYL) 3 (4 HYDROXYCYCLOHEXYL) 1 NITROSOUREA];

ANIMAL EXPERIMENT; ARTICLE; DOG; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; NONHUMAN;

CANIS FAMILIARIS;

EID: 74549140910     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/33.9.595     Document Type: Article

References (23)

1. E.P. Mitchell and P.S. Schein. Contributions of nitrosoureas to cancer treatment. Cancer Treat. Rep. 70: 31-38 (1986).
2. K.D. Tew, O.M. Coluin, and R.B. Jones. Clinical and high-dose akylating agents. In Cancer Chemotherapy and Biotherapy, B.A. Chabner and D.L. Longo, Eds, 4th ed. Lippincott Williams & Wilkins, Philadelphia, PA, 2006, pp 283-309.
3. J. Hilton and M.D.Walker. Hydroxylation of 1-(2-chloroethyl)-3- cyclohexyl-1-nitrosourea. Biochem. Pharmacol. 24: 2153-2158 (1975).
4. P. Kari, W.B. McConnell, J.M. Finkel and D.L. Hill. Distribution of Bratton-Marshall-positive material in mice following intravenous injections of nitrosoureas. Cancer Chemother. Pharmacol. 4: 243-248 (1980).
5. F.Y.F. Lee, P. Workman, J.T. Roberts and N.M. Bleehen. Clinical Pharmacokinetics of oral CCNU (lomustine). Cancer Chemother. Pharmacol. 14: 125-131 (1985).
6. H. Kastrissios, N.J. Chao, and T.F. Blaschke. Pharmacokinetics of high dose oral CCNU in bone marrow transplant patients Cancer Chemother. Pharmacol. 38: 425-430 (1996).
7. M.L. Sauerbrey, M.N. Mullins, E.O. Bannink, T.E. Van Dorp, J.B. Kaneene, and J.E. Obradovich. Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005). J. Am. Vet.Med. Assoc. 230(12): 1866-1869 (2007).
8. F.C. Saba, D.H. Thamm, and D.M. Vail. Combination chemotherapy with L-asparaginase, Lomustine, and Prednisone for relapsed or refractory canine lymphoma. J. Vet. Intern. Med. 21(1): 127-132 (2007).
9. A.S. Moore, C.A. London, C.A.Wood, L.E. Williams, S.M. Cotter, D.A. L'Heureux, and A.E. Frimberger. Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. J. Vet. Intern. Med. 13: 395-398 (1999).
10. K.M. Rassnick, A.S. Moore, L.E. Williams, C.A. London, P.P. Kintzer, S.J. Engler, and S.M. Cotter. Treatment of canine mast cell tumors with CCNU (lomustine). J. Vet. Intern. Med. 13(6): 601-605 (1999).
11. D.I. Jung, H.J. Kim, C. Park, J.W. Kim, B.T. Kang, C.Y. Lim, E.H. Park, J.H. Sur, M.H. Seo, D.H. Hahm, and H.M. Park. Longterm chemotherapy with lomustine of intracranial meningioma occurring in a miniature schnauzer. J. Vet. Intern. Med. 68(4): 383-386 (2006).
12. L.E.Williams, K.M. Rassnick, H.T. Power, S.E. Lana, K.E. Morrison-Collister, K. Hansen, and J.L. Johnson. CCNU in the treatment of canine epitheliotropic lymphoma. J. Vet. Intern. Med. 20(1): 136-143 (2006).
13. K.A. Skorupski, C.A. Clifford, M.C. Paoloni, A. Lara-Garcia, L. Barker, M.S. Kent, A.K. LeBlanc, A. Sabhlok, E.A. Mauldin, F.S. Shofer, C.G. Couto, and K.U. Sørenmo. CCNU for the treatment of dogs with histiocytic sarcoma. J. Vet. Intern. Med. 21(1): 121-126 (2007).
14. D.M. Vail, E.G. MacEwen, and K.M. Young. Canine lymphoma and lymphoid leukemia. In Small Animal Clinical Oncology, 3rd ed., S.J.Withrow, Ed. W.B. Saunders Co., Philadelphia, PA, 2001, pp 558-590.
15. W.B. Morrison. Lymphoma in Dogs and Cats. Teton NewMedia, Jackson, WY, 2005, pp 54-56.
16. R.J. Weinkam and H.S. Lin. Chloroethylnitrosourea cancer chemotherapeutic agents. Adv. Pharmacol. Chemother. 19: 1-33 (1982).
17. G.P. Wheeler, T.P. Johnston, B.J. Bowdon, G.S. McCaleb, D.L. Hill, and J.A. Montgomery. Comparison of the properties of metabolites of CCNU. Biochem. Pharmacol. 26(24): 2331-2336 (1977).
18. T.K.H. Chang, G.F. Weber, C.L. Crespi, and D.J. Waxman. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res. 53(23): 5629-5637 (1993).
19. K.R. Zhou-Pan, E. Seree, X.J. Zhou, M. Placidi, P. Maurel,Y. Barra, and R. Rahmani. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: drug interactions. Cancer Res. 53(21): 5121-5126 (1993).
20. F.Y.H. Lee and P.Workman. Modification of CCNU pharmacokinetics by misonidazole - a major mechanism of chemosensitization in mice. Br. J. Cancer 47(5): 659-669 (1983).
21. T.P. Johnston, G.S. McCaleb, and J.A. Montgomery. Synthesis and biologic evaluation of major metabolites of N-(2-chloroethyl)-N′-cyclohexyl-N- nitrosourea. J. Med. Chem. 18(6): 634-637 (1975).
22. P. Roger, C. Monneret, J.P. Fournier, P. Choay, R. Gagnet, C. Gosse,Y. Letourneux, G. Atassi, and A. Gouyette. Rationale for the synthesis and preliminary biological evaluation of highly active new antitumor nitrosoureido sugars. J. Med. Chem. 32(1): 16-23 (1989).
23. H.E. May, R. Boose, and D.J. Reed. Microsomal monooxygenation of the carcinostatic 1-(2-chlroethyl)-3-cyclohexyl-1-nitrosourea. Synthesis and identification of cis and trans monohydroxylated products. Biochemistry 14(21): 4723-4730 (1975).